By Q4 2027, vendor-backstopped SPVs fund most new frontier AI accelerator purchases

The claim

By the end of Q4 2027, the majority of newly committed frontier-AI accelerator capacity (measured by dollar value of chips purchased for the largest US labs — Anthropic, OpenAI, xAI, and their immediate peers) will be funded through off-balance-sheet special-purpose vehicles using structured/asset-backed credit, rather than through cash, standard corporate debt, or straightforward equity. Furthermore, at least three of these large 2026-2027 SPV financings will feature an explicit vendor residual-value backstop or guarantee from a chip supplier (e.g., Broadcom, Nvidia, or AMD) on the senior tranches — making the vendor-wrap structure pioneered by Anthropic's June 2026 deal the dominant template rather than a one-off.

The reasoning

The economics are nearly irresistible for every party at the table, which is exactly why structures replicate. Anthropic's ~$35 billion Apollo/Blackstone TPU SPV closed in June 2026 with three debt tranches: ~$6B A1 at roughly Treasuries+100bps, ~$24B A2 near a 5.75% coupon, and ~$4.5B of B notes near 8.5%. The roughly 275-basis-point gap between the backstopped A2 and the unbackstopped B notes is the market quantifying the value of the Broadcom residual-value guarantee — several hundred million dollars a year in saved interest on the senior layers. Once one issuer demonstrates that a vendor wrap converts volatile, fast-depreciating collateral into investment-grade senior paper, every subsequent issuer and arranger has a strong incentive to demand the same.

The off-balance-sheet base is already enormous and growing. By late 2025, tech firms had moved over $120 billion of AI infrastructure debt off their balance sheets through SPVs — Meta's ~$30B Hyperion deal with Blue Owl, Oracle's multiple OpenAI-linked vehicles, xAI and CoreWeave structures. The same small set of arrangers (Apollo, Blackstone, Blue Owl, PIMCO, BlackRock) recurs across these deals, and private credit is sitting on record dry powder hunting for yield. The pre-IPO and balance-sheet-optics incentives that drove Anthropic to keep $35B off its S-1 apply to every lab racing toward a public listing or a clean capital structure.

The vendor backstop specifically should spread because it solves the one thing that makes accelerator securitization hard: there is no stable, decades-deep resale market for AI chips the way there is for aircraft. The chip vendors are the only parties with both the balance sheet and the informational edge to underwrite residual value, and they have a powerful sales incentive to do so — the wrap moves more silicon. That is the same incentive that produced telecom vendor financing in the late 1990s.

What would confirm it

• Public reporting or filings showing that, across the largest US labs in 2027, more than half of new accelerator purchase value is routed through off-balance-sheet SPVs.
• At least three distinct 2026-2027 large AI-accelerator SPV financings (beyond the Anthropic deal) disclosing an explicit chip-vendor residual-value guarantee or backstop on senior tranches.
• Rating agencies publishing methodology that treats vendor residual-value wraps as a recognized credit-enhancement category for AI hardware ABS.

What would refute it

• Frontier labs predominantly funding 2027 accelerator purchases via cash, on-balance-sheet corporate debt, or equity, with SPVs remaining a minority of dollar volume.
• The Anthropic Broadcom backstop remaining a structural one-off, with subsequent SPVs declining vendor wraps (e.g., because vendors refuse the concentration, or rating agencies decline to credit them).
• A market dislocation that freezes private-credit AI infrastructure issuance entirely, such that "majority via SPV" never gets the chance to materialize.

Confidence

Set at 68. The directional trend — toward off-balance-sheet SPV financing — is already firmly established and very likely to continue. The genuine uncertainty is the second, sharper condition: whether the vendor-backstop feature specifically becomes standard across at least three more large deals within 18 months, versus remaining a distinctive Anthropic/Broadcom arrangement. Vendor willingness to repeatedly concentrate residual-value risk, and rating-agency treatment of those wraps, are the swing variables that keep this below a higher confidence tier.